Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

New Strategies to Enhance Myocardial Regeneration: Expectations and Challenges from Preclinical Evidence

Rurali E., Vinci MC., Bassetti B., Barbagallo V., Pompilio G., Gambini E.

Clinical Trial on Cardiovascular Disease, published in Curr Stem Cell Res Ther (2020) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Curr Stem Cell Res Ther (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32096748
PMCID
PMC8493790
DOI
10.2174/1574888x15666200225124451
Citations
5

Abstract (original English)

Nowadays, cardiac regeneration is an emerging topic in the cardiovascular field because of the compelling need for effective therapies for repairing or replacing cardiac tissue damaged by pathological or physiological conditions. Indeed, irreversible myocardial remodeling which follows acute myocardial infarction represents a serious burden of this century. In this context, a great improvement in pharmacological and interventional techniques is accompanied by a big challenge of cardiac regenerative medicine. In the last 20 years, several clinical trials tried to investigate the role of different types of stem cells in promoting cardiac repair. However, the promising results obtained in the preclinical trials have not yet been reproduced in patients. Thus, the development of novel strategies to improve stem cell efficiency became imperative. Here, an overview of the more recent cell types proposed for cardiac regeneration is presented, together with the most interesting approaches to enhance cell regenerative potential as well as cell-free approaches.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
MyocardiumHeartMyocytes, CardiacHumansMyocardial InfarctionStem Cell TransplantationRegenerative MedicineRegeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research